{"product_id":"biolegend-100218","title":"Biolegend, 100218, PerCP\/Cyanine5.5 anti-mouse CD3 Antibody, 100μg","description":"\u003cp\u003eCD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α\/β or γ\/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide\/MHC antigen complex\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: γδTCR-positive T-T hybridoma D1\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PerCP\/Cyanine5.5 under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.* PerCP\/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Chen Y, et al. 2020. Virol Sin. . PubMed Abraham A, et al. 2019. J Clin Invest. 130:2685. PubMed Li SX, et al. 2019. PLoS Pathog. 15:e1007611. PubMed Kawabe T, et al. 2020. Nat Commun. 2.795833333. PubMed Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed Aso K, et al. 2023. Nat Commun. 14:984. PubMed Wang Y, et al. 2023. EBioMedicine. 90:104480. PubMed Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed Wiedmann L, et al. 2023. Nat Commun. 14:2353. PubMed Wang Y, et al. 2023. iScience. 26:106630. PubMed Wang K, et al. 2023. Nat Commun. 14:2950. PubMed Tsugawa H, et al. 2023. PLoS Pathog. 19:e1011139. PubMed Wang X, et al. 2023. Nat Commun. 14:3440. PubMed Zhou M, et al. 2023. Nat Commun. 14:3593. PubMed Song S, et al. 2023. Bioact Mater. 28:358. PubMed Guo X, et al. 2023. Mol Immunol. 160:32. PubMed Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed Cautivo KM, et al. 2022. Immunity. 55:254. PubMed Wang H, et al. 2022. Immunol Cell Biol. 100:547. PubMed Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed Rodrigues PB, et al. 2022. Cells. 11: . PubMed Chen X, et al. 2022. J Extracell Vesicles. 11:e12279. PubMed Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed Tunali G, et al. 2023. J Clin Invest. :. PubMed Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed Pessoa Rodrigues C, et al. 2021. Sci Adv. 7:. PubMed Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed Molofsky A, et al. 2013. J Exp Med. 210:535. PubMed Han Y, et al. 2020. Nat Commun. 11:1776. PubMed Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed Burrack KS et al. 2018. Immunity. 48(4):760-772 . PubMed Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed Cai B, et al. 2021. Mol Cancer. 20:165. PubMed Yang F, et al. 2020. Cancer Res. 80:3677. PubMed Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed Jin Q, et al. 2022. Drug Des Devel Ther. 16:3297. PubMed Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed Yang K, et al. 2022. J Clin Invest. 132:. PubMed Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Chakraborty S, et al. 2022. Sci Transl Med. . PubMed Mamedov MR, et al. 2018. Immunity. 48:350. PubMed Soutto M, et al. 2017. J Cancer. 8:2424. PubMed Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed Vettorazzi S, et al. 2015. Nat Commun. 6: 7796. PubMed Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed Ercoli G, et al. 2022. Clin Transl Immunology. 11:e1366. PubMed Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed Fu Z, et al. 2021. Cell Res. 31:631. PubMed Colombo M, et al. 2022. iScience. 25:105042. PubMed Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed Agarwal P, et al. 2019. Cell Stem Cell. 24:769. PubMed Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed Qadir AS, et al. 2021. iScience. 24:103348. PubMed Zhou J, et al. 2022. Int J Oncol. 61: . PubMed Al-Barwani F, et al. 2014. PLoS One. 9:104523. PubMed Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed Bennett FC, et al. 2018. Neuron. 98:1170. PubMed Shehata L, et al. 2019. Cell Rep. 28:3300. PubMed Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed Laubreton D, et al. 2020. Viruses. 12:00. PubMed Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed Reda M, et al. 2022. Nat Commun. 13:4261. PubMed Zheng Y, et al. 2022. J Immunol. 208:501. PubMed Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Knox T, et al. 2019. Sci Rep. 9:6136. PubMed Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed Kim S, et al. 2022. Cancers (Basel). 14:. PubMed Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed Jiang Y, et al. 2015. MBio. 6: e01426-15. PubMed Sun Y, et al. 2022. iScience. 25:104846. PubMed Agarwal P, et al. 2021. Cell Reports. 36(2):109386. PubMed Konishi Y, et al. 2018. iScience. 10:98. PubMed Lai NY, et al. 2020. Cell. 180:33:00. PubMed Chirivi RGS, et al. 2020. Cell Mol Immunol. . PubMed Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed Riopel M, et al. 2019. Mol Metab. 20:89. PubMed Song X, et al. 2022. Transl Oncol. 15:101306. PubMed\u003cbr\u003e\nRRID: AB_1595597 (BioLegend Cat. No. 100217) AB_1595492 (BioLegend Cat. No. 100218)\u003cbr\u003e\nStructure: Ig superfamily, CD3\/TCR, 20 kD\u003cbr\u003e\nDistribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells\u003cbr\u003e\nFunction: Antigen recognition, TCR signal transduction, T cell activation\u003cbr\u003e\nLigand\/Receptor: Peptide antigen\/MHC-complex\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.\u003cbr\u003e\nGene ID: 12502\u003cbr\u003e\nUniProt: View information about CD3 on UniProt.org\u003cbr\u003e\nClone: 17A2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T cell antigen receptor complex, T3\u003cbr\u003e\nIsotype: Rat IgG2b, κ\u003cbr\u003e\nQ: How stable is PerCP\/Cyanine5.5 tandem as compared to PerCP alone?\u003cbr\u003e\nA: PerCP\/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860823986345,"sku":"100218","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-100218","provider":"Iright","version":"1.0","type":"link"}